Vestibular Schwannoma Clinical Trial
Official title:
Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife
The purpose of this study is to evaluate the vestibular effects of gamma-knife radiosurgery, as part of the treatment of vestibular schwannoma.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | November 1, 2024 |
Est. primary completion date | November 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria : - Men and women aged 18 to 90 included - Subject who benefited from gamma-knife radiosurgery as part of the treatment of vestibular schwannoma - Non-opposition of the subject to participate in the study - Affiliation to a French social security scheme or beneficiary of such a scheme Exclusion Criteria : - Subject with another vestibular pathology - Subject who did not benefit from a vestibular assessment before treatment with gamma-knife radiosurgery - Legal incapacity or limited legal capacity - Subject unlikely to cooperate in the study and/or weak cooperation anticipated by the investigator - Subject without health insurance - Subject being in the period of exclusion from another study or provided for by the "national volunteer file". |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Besancon |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Description of vestibular function with videonystagmography before gamma-knife radiosurgery, as part of the treatment of vestibular schwannoma. | Videonystagmography: Results of caloric tests = Intervestibular deficit (in percentage) | 1 month before gamma-knife radiosurgery | |
Primary | Description of vestibular function with vidéonystagmoscopy before gamma-knife radiosurgery, as part of the treatment of vestibular schwannoma. | Videonystagmography: Results of caloric tests = Intervestibular deficit (in percentage) | After gamma-knife radiosurgery at 6 month or 12 month or 18 month or 2 years or 3 years depending on the history of the treatment | |
Secondary | Description of vestibular symptoms before gamma-knife radiosurgery as part of the treatment of vestibular schwannoma. | Dizziness Handicap Inventoryquestionnaire (DHI questionnaire) | 1 month before gamma-knife radiosurgery | |
Secondary | Description of vestibular symptoms after gamma-knife radiosurgery as part of the treatment of vestibular schwannoma. | Dizziness Handicap Inventoryquestionnaire (DHI questionnaire) | After gamma-knife radiosurgery at 6 month or 12 month or 18 month or 2 years or 3 years depending on the history of the treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Active, not recruiting |
NCT00973739 -
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
Completed |
NCT04351373 -
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
|
Phase 2 | |
Active, not recruiting |
NCT01449604 -
Stereotactic Radiation in Vestibular Schwannoma
|
Phase 3 | |
Completed |
NCT01207687 -
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
|
Phase 2 | |
Not yet recruiting |
NCT05567341 -
Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery
|
N/A | |
Completed |
NCT02249572 -
Vestibular Schwannoma - Radiosurgery or Expectation: V-REX.
|
N/A | |
Terminated |
NCT05116878 -
Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma
|
N/A | |
Suspended |
NCT03095248 -
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
|
Phase 2 | |
Recruiting |
NCT04801953 -
Nimodipine in Vestibular Schwanommas
|
Phase 2 | |
Recruiting |
NCT03745560 -
Intraoperative EABR for Decision Making
|
||
Recruiting |
NCT04859335 -
Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma
|
N/A | |
Recruiting |
NCT04128345 -
Novel Multimodality Imaging for Navigation in Skull Base Surgery
|
||
Active, not recruiting |
NCT01199978 -
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
|
Phase 2 | |
Recruiting |
NCT04057976 -
Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas
|
N/A | |
Completed |
NCT00863122 -
Concentration and Activity of Lapatinib in Vestibular Schwannomas
|
Early Phase 1 | |
Recruiting |
NCT04374305 -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
|
Phase 2 | |
Recruiting |
NCT03079999 -
Study of Aspirin in Patients With Vestibular Schwannoma
|
Phase 2 | |
Recruiting |
NCT05786144 -
Vestibular Schwannoma Organoids
|
||
Recruiting |
NCT03593577 -
Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI
|